的前景，复宏汉霖将以后准确把握药学和行业未被要求的供需，发掘非常多健康性强、成效好的、提高可付出的特色化生物学药类产品，定期进行强化研究开发、生產及金融业化的全球各地各地运营的制度，探讨非常多国.际化达成合作将，新一轮加速器国.际化的进程，造福全球各地各地非常多提高受众群体。

Henlius Attends BIO 2022

From June 13-16, 2022, the 2022 Biotechnology Innovation Organization International Convention (“BIO 2022”) was held in San Diego, California, USA. The conference attracted more than 3,000 exhibitors, as well as many global industry leaders and top research scholars. At the San Diego Convention Center’s booth 5107, Henlius showcased a wide range of innovative research and development accomplishments for conference attendees.

During the conference, Henlius ended with more than 90 meetings with national and international partners and multiple possible leads for in-licensing, research collaboration, or commercial right out-licensing conducted at the Henlius’ booth throughout the four-day exhibition. These discussions focused on advancing new approaches to science, including therapeutic biologics, technology platforms, immuno-oncology target combinations, and building robust partnerships to accelerate innovation. Henlius’ diversified product pipeline and international presence was attractive to attendees. Most impressive is Henlius' leading innovative product, HANSIZHUANG (serplulimab), which was the first China-based company developed anti-PD-1 mAb to be orally presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting for the first-line treatment of lung cancer. Subsequently, Henlius announced on the first day of BIO 2022 that it had entered into a license and supply agreement with Organon LLC for the exclusive global commercialization of Henlius independently developed HLX11 (Pertuzumab biosimilar) and HLX14 (Denosumab biosimilar) in ex-China countries, including mature markets such as the United States, the European Union and Japan, as well as emerging markets.

Having the goals of providing innovation and affordability for patient centric unmet medical needs, Henlius has actively expanded the global markets by leveraging its strong product development, manufacturing and quality systems, and commercialization capabilities, as well as collaborating with capable partnerships to accelerate these goals. Synergising its innovation centres in China and the US and global product development teams, the company continues to build on the momentum to expand an even more diversified innovation product pipeline and has conducted more than 20 clinical trials in China, the EU, the US, Australia, etc. with more than 70 clinical trial approvals worldwide. In terms of manufacturing, the company strictly follows the International Good Manufacturing Practice (GMP) standards for production and quality control. It has a total commercial manufacturing capacity of 48,000L currently, and all the products in the pipeline are produced in-house, accumulating vertically integrating production experience and capabilities from clinical stages to commercialized products. In terms of commercialization, Henlius has built a top tier in-house commercial team of over 800 sales force for the commercialization of the company's core oncology products such as HANQUYOU (trastuzumab biosimilar, Zercepac^® in Europe) and HANSIZHUANG. In addition, Henlius has actively collaborated with global partners such as Abbott, Accord, Cipla, Eurofarma, Organon, Jacobson Medical, KG Bio, FARMA DE COLOMBIA, and Mabxience to expand the global presence of bring innovative medicines and affordability to patients both in major and emerging markets.

Looking forward, Henlius will maintain its focus on unmet medical and market needs; develop more high-quality, affordable and innovative biologics; advance its global R&D, production, and commercialization capabilities; expand international collaborations, and accelerate building a global presence to benefit patients worldwide.